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Abstract The cholinergic theory of depression highlights
the involvement of muscarinic acetylcholine receptors in the
neurobiology of mood disorders. The present study was
designed to investigate the effect of sildenafil, a phospho-
diesterase type 5 inhibitor which exhibits cholinomimetic
properties, alone and in combination with scopolamine in the
forced swim test in mice. Moreover, we assessed the ability
of sildenafil to modify the antidepressant activity of two
tricyclic antidepressants with distinct cholinolytic activity,
amitriptyline and desipramine. Swim sessions were con-
ducted by placing mice in glass cylinders filled with water
for 6 min and the duration of behavioral immobility during
the last 4 min of the test was evaluated. Locomotor activity
was measured with photoresistor actimeters. To evaluate the
potential pharmacokinetic interaction between amitriptyline
and sildenafil, brain and serum concentrations of amitripty-
line were determined by HPLC. Sildenafil (1.25–20 mg/kg)
as well as scopolamine (0.5 mg/kg) and its combination
with sildenafil (1.25 mg/kg) did not affect the total
immobility time duration. However, joint administration of
scopolamine with sildenafil at doses of 2.5 and 5 mg/kg
significantly reduced immobility time as compared to
control group. Moreover, co-administration of scopolamine
with sildenafil at the highest dose (5 mg/kg) significantly
decreased immobility time as compared to scopolamine-
treated group. Sildenafil (1.25, 2.5 and 5 mg/kg) signifi-
cantly enhanced the antidepressant activity of amitriptyline
(5 mg/kg). No changes in anti-immobility action of desi-
pramine (20 mg/kg) in combination with sildenafil (5, 10
and 20 mg/kg) were observed. Sildenafil did not affect
amitriptyline level in both brain and serum. In conclusion,
the present study suggests that sildenafil may enhance the
activity of antidepressant drugs which exhibit cholinolytic
activity.
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Introduction
Depressive disorder is one of the most prevalent and dis-
abling mental disorders which affects up to 20% of indi-
viduals at some point of their life (Pacher and Kecskemeti
2004). By 2020, depression is expected to become the
second leading contributor to the global burden of disease
worldwide (Murray and Lopez 1997). Depressed mood, loss
of interest, feelings of worthlessness or inappropriate guilt,
decrease in appetite and libido, insomnia and recurrent
thoughts of death or suicide are the most common symp-
toms of depression (Maletic et al. 2007; Krishnan and
Nestler 2008). Despite the widespread nature of depression,
little is known about its etiology and pathophysiology.
Interactions between genetic predispositions and environ-
mental risk factors are thought to contribute to mood dis-
orders (Jabbi et al. 2008). Due to complexity and
heterogeneous character of depression, several distinct
concepts regarding neurobiology of mood disorders have
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emerged. Among them, the monoamine theory of depres-
sion has gained the largest popularity (Nestler et al. 2002;
Ansorge et al. 2007). This hypothesis proposes that
depressive disorders are caused by deficits in serotonergic,
noradrenergic and dopaminergic neurotransmitters systems.
Although many experimental and clinical studies clearly
implicated the involvement of monoamines in pathophysi-
ology of depressive disorders, the monoaminergic hypoth-
esis does not provide sufficient explanation for mechanism
underlying depression and mode of action of antidepressant
drugs (Manji et al. 2001; Krishnan and Nestler 2008).
Several lines of evidence indicate that hyperfunction of
cholinergic neurotransmission contributes to depression
(Pacher and Kecskemeti 2004; Mineur and Picciotto 2010).
The so-called cholinergic–adrenergic theory of affective
disorders was proposed for the first time almost 40 years
ago by Janowsky et al. (1972). They assumed that the
affective state is a result of balance between cholinergic
and adrenergic neurotransmission in specific brain regions
and that depression is associated with hyperactivity of
cholinergic system while mania is a disease of hypocho-
linergic states (Janowsky et al. 1972, 1974). This hypoth-
esis is consistent with observations that arecoline (a
cholinomimetic) and physostigmine (an acetylcholinester-
ase inhibitor), presumably via muscarinic acetylcholine
receptors, induce depression-like symptoms such as
depressed mood, dysphoria, anhedonia and behavioral
withdrawal in healthy volunteers (Janowsky et al. 1974;
Dilsaver 1986; Mearns et al. 1994; Mineur and Picciotto
2010). On the basis of the theory that altered cholinergic
neurotransmission leads to depression, the selective breed-
ing program resulted in introduction of a strain of rats,
called the Flinders Sensitive Line (FSL) rats, which are
characterized by increased sensitivity to diisopropyl fluo-
rophosphate, an acetylcholinesterase inhibitor. The FSL rats
also exhibit certain behavioral symptoms of depression
including reduced psychomotor activity and appetite
(Overstreet and Russell 1982; Overstreet et al. 2005).
Moreover, increased cholinergic activity was observed in
rats subjected to swim stress (Dilsaver et al. 1986) and
human post mortem studies revealed increased muscarinic
receptors level in the brains of suicide victims (Meyerson
et al. 1982). It has also been suggested that muscarinic
receptors within the nucleus accumbens play a key role in
the control of immobility state in the forced swim test in
rodents (Chau et al. 1999, 2001). Further support for the
idea that hyperfunction of muscarinic receptors may be
involved in pathophysiology of depression provides results
of clinical trials. The studies showed rapid and potent
antidepressant response to antimuscarinic agent, scopol-
amine, in patients suffering from major depressive disorder
and bipolar disorder (Furey and Drevets 2006; Drevets and
Furey 2010).
Sildenafil, an active compound of Viagra, is the first-
line oral treatment for erectile dysfunctions of multiple
etiologies (Rosen and McKenna 2002; Nurnberg and
Hensley 2003). Mechanism of action of sildenafil involves
the nitric oxide/cyclic guanosine 30,50-monophosphate/
phosphodiesterase type 5 (NO/cGMP/PDE5) cell signaling
pathway. Sildenafil works as a selective inhibitor of PDE5.
By inhibiting cGMP degradation, it improves the relaxation
of the smooth muscles in the corpus cavernosum and leads
to erection (Ghofrani et al. 2006). Sildenafil exerts various
effects on the central nervous system. The recent data show
that it possesses neuroprotective properties, enhances
neurogenesis and improves memory (Uthayathas et al.
2007). Furthermore, it has been showed that sildenafil,
administered chronically, elevates muscarinic acetylcho-
line receptor signaling capacity in rats and exerts antide-
pressant-like properties in the forced swim test, a widely
used animal model for screening antidepressants, after pre-
treatment with atropine, a muscarinic receptor antagonist
(Brink et al. 2008; Liebenberg et al. 2010a, b).
Therefore, the aim of the present study was to investi-
gate the effect of sildenafil administered acutely on the
animal behavior in the forced swim test in mice and to
evaluate the anti-immobility action of sildenafil after cen-
tral muscarinic receptor blockade with scopolamine. Since
sildenafil possesses antidepressant properties which are
attenuated because of its simultaneous cholinotropic effect
(Brink et al. 2008; Liebenberg et al. 2010a, b), we pre-
sumed that it would potentiate the activity of amitriptyline,
a commonly used antidepressant drug which exhibits
cholinolytic properties (Snyder and Yamamura 1977;
McKinney et al. 1988), and that it should not affect the
activity of antidepressants devoid of antimuscarinic action,
such as desipramine (Nelson 2009). To evaluate the
potential pharmacokinetic interaction between amitripty-
line and sildenafil, total brain and serum concentrations of
amitriptyline were determined.
Materials and methods
Animals
Experimentally naı¨ve male Albino Swiss mice (Laboratory
Animals Breeding, Słaboszo´w, Poland) weighing 25–30 g
were used in all experiments. The animals were housed in
groups of 7–8 in polycarbonate cages at a controlled tem-
perature (23–25C), and humidity (50–60%) with 12 h
light/dark cycle (lights on at 6:00 h). Tap water and food
pellets (Agropol S.J., Motycz, Poland) were available
ad libitum. All experiments were performed after at least
7 days of acclimatization. The experimental protocols were
approved by the Ethical Committee of the Medical
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University in Lublin (license numbers 64/2007 and
69/2009). All procedures were in strict compliance with the
European Communities Council Directive of 24 November
1986 (86/609/EEC).
Drugs
Sildenafil citrate (kindly provided by Polpharma S.A.,
Starogard Gdan´ski, Poland), scopolamine methyl bromide
(Sigma, Steinheim, Germany) and amitriptyline hydro-
chloride (kindly provided by ICN Polfa Rzeszo´w, Rzes-
zo´w, Poland) were dissolved in saline and administered
30 min before the respective test. Desipramine (Petylyl,
AWD.pharma GmbH & Co. KG, Dresden, Germany) was
suspended in a 0.5% aqueous solution of methyl cellulose
(Sigma, Steinheim, Germany) and administered 60 min
prior to the tests. All solutions and suspensions were pre-
pared freshly and administered intraperitoneally (i.p.) in a
volume of 0.1 ml per 10 g body weight. Control animals
received an i.p. injection of a respective vehicle. The doses
and pretreatment schedules were selected based on those
reported in the literature and previous experiments in our
laboratory (Karolewicz and Paul 2001; Kurt et al. 2004;
Ushijima et al. 2005; Nieoczym et al. 2010a, b).
Forced swim test
The test was conducted according to the method described
by Porsolt et al. (1977). Mice were placed individually into
glass cylinders (height 25 cm, diameter 10 cm). The cyl-
inders contained 10 cm of water maintained at temperature
23–25C. Animals were allowed to swim for 6 min. The
total duration of immobility was recorded during the last
4 min of the test. The duration of immobility was defined
as the time when the mouse remained floating passively,
made no attempts to escape and showed only slow move-
ments to keep its head above the water.
Locomotor activity
The actimeter consists of a cylinder (30 cm diameter,
12 cm high, MultiServ, Lublin, Poland) equipped with two
perpendicular infrared light beams located 1.5 cm above
the floor. Mice were i.p. pretreated with respective drugs or
drug combinations and after a given time period they were
placed in the actimeter, and locomotor activity (number of
interruptions of light beams) was recorded for a period of
10 min after placing the mouse into the actimeter.
Amitriptyline determination
Serum and brain concentrations of amitriptyline were
determined by high performance liquid chromatography
(HPLC) method. After drug pretreatment, mice were
sacrificed by decapitation. The trunk blood was collected
into polyethylene tubes. Serum was isolated 1h after
blood coagulation by centrifugation at 5,0009g for
10 min at 4C and frozen at -30C. The brains were
rapidly removed after decapitation, washed in saline and
frozen on dry ice.
200 ll of serum was mixed with 10 ll of imipramine
solution in methanol as an internal standard. The samples
were alkalized with 200 ll of 2M sodium hydroxide and
extracted with 3 ml of ethyl acetate:hexane (30:70, v/v).
Likewise, 1 ml of brain homogenate was mixed with 20
ll of imipramine solution, alkalized with 500 ll of 2 M
sodium hydroxide and extracted with 5 ml of dichloro-
methane:hexane:isoamyl alcohol (40:60:1, v/v/v). All
samples were then shaken for 20 min (IKA VXR Vibrax,
Germany). After centrifugation (1,5009g for 15 min),
the organic layer was transferred to a new tube, and
evaporated to dryness at 37C under a stream of nitro-
gen. The residue was dissolved in 100 ll of methanol
and 50 ll of this solution was injected into the HPLC
system.
The HPLC system (Thermo Separation Products, San
Jose, CA, USA) consisted of a P100 isocratic pump, a
Rheodyne 7125 injector (Rheodyne, Cotati, CA, USA)
with a 50 ll sample loop, a UV100 Variable-wavelength
UV/VIS detector, operating at 214 nm and a SP4400
(Thermo Separation Products, San Jose, CA, USA)
integrator. All analysis were performed at ambient tem-
perature (21C) on a 250 9 4.6 mm LiChrospher100
RP-18 column (Merck, Darmstadt, Germany) with 5 lm
particles, protected with a guard column (4 x 4 mm) with
the same packing material. The mobile phase consisted
of acetonitrile:50 mM potassium dihydrogen phosphate
pH 3.5 (40:60, v/v) and was pumped at a flow rate of
1 ml/min.
The calibration curves were linear in the tested con-
centration ranges. The assay was reproducible with low
intra- and inter-day variation (coefficient of variation less
than 10%). Serum and brain concentrations of amitriptyline
were expressed in ng/ml and ng/g of fresh tissue,
respectively.
Statistics
All results are presented as mean ± standard error of the
mean (SEM). Data obtained in behavioral tests were
evaluated using one-way analysis of variance (one-way
ANOVA) followed by the Tukey’s post hoc test for mul-
tiple comparisons. Serum and brain concentrations of
amitriptyline were compared by unpaired Student’s t test.
Statistical significance was noted when p values were equal
to or less than 0.05.
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Results
Forced swim test
The first series of experiments was performed to evaluate
the effect of sildenafil at doses of 1.25–20 mg/kg on
immobility time in the forced swim test in mice. As shown
in Fig. 1, sildenafil at any doses tested did not alter the total
immobility duration as compared to the saline-treated
group [ANOVA: F(5, 55) = 0.321, p = 0.898].
The effect of scopolamine (0.5 mg/kg) alone and in
combination with sildenafil on immobility time in the forced
swim test in mice is shown in Fig. 2 [ANOVA: F(4, 45) =
7.205, p \ 0.001]. Scopolamine, as well as a combination of
scopolamine with sildenafil at a dose of 1.25 mg/kg, did not
alter the total immobility duration as compared to the control
group (p [ 0.05). However, joint administration of scopol-
amine with sildenafil at a dose of 2.5 mg/kg significantly
reduced immobility time as compared to control group
(p \ 0.05) but not scopolamine-treated group (p \ 0.05).
Co-administration of scopolamine with sildenafil at the
highest dose (5 mg/kg) caused further decrease in the total
immobility duration (p \ 0.001 vs. saline-treated group).
Additionally, the Tukey’s post hoc test revealed that the
observed difference was statistically significant as compared
to scopolamine-treated group (p \ 0.01).
The influence of sildenafil on the antidepressant activity
of amitriptyline (5 mg/kg) in the forced swim test in mice
is shown in Fig. 3 [ANOVA: F(4, 49) = 82.355,
p \ 0.001]. Sildenafil at the lowest dose tested, i.e.,
1.25 mg/kg, significantly enhanced the antidepressant
activity of amitriptyline (p \ 0.05). Higher doses of sil-
denafil (2.5 and 5 mg/kg) caused further increase in the
anti-immobility action of amitriptyline (p \ 0.001).
Figure 4 depicts the effect of joint administration of
desipramine (20 mg/kg) and sildenafil on the immobility
duration in mice [ANOVA: F(4, 69) = 9.095, p \ 0.001].
Desipramine administered alone significantly reduced
immobility time as compared to control group while sil-
denafil at any dose tested (5, 10 and 20 mg/kg) neither
enhanced nor diminished the antidepressant activity of
desipramine (p [ 0.05 as compared to the desipramine-
treated group).
Locomotor activity
The data obtained in spontaneous locomotor activity test
are presented in Table 1. No significant alterations in
locomotor activity with either drug or their combinations
were demonstrated.
Fig. 1 Effect of sildenafil on immobility time in the forced swim test
in mice. Sildenafil was administered i.p. 30 min before the test.
Control animals received saline. Each experimental group consisted
of 10–11 animals. Data are presented as mean ? SEM
Fig. 2 Effect of scopolamine administered alone and in combination
with sildenafil on immobility time in the forced swim test in mice.
Both drugs were administered i.p. 30 min before the test. Control
animals received saline. Each experimental group consisted of
9–11 animals. Data are presented as mean ? SEM. *p \ 0.05,
***p \ 0.001 as compared to saline-treated group; ##p \ 0.01 as
compared to scopolamine-treated group (one-way ANOVA followed
by the Tukey’s post hoc test)
Fig. 3 Effect of amitriptyline administered alone and in combination
with sildenafil on immobility time in the forced swim test in mice.
Both drugs were administered i.p. 30 min before the test. Control
animals received saline. Each experimental group consisted of 9–12
animals. Data are presented as mean ? SEM. ***p \ 0.001 as
compared to saline-treated group; #p \ 0.05, ###p \ 0.001 as com-
pared to amitriptyline-treated group (one-way ANOVA followed by
the Tukey’s post hoc test)
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Pharmacokinetic studies
The effect of combined administration of amitriptyline and
sildenafil on serum and brain amitriptyline concentrations
in mice is shown in Table 2. Co-administration of sildenafil
at a dose of 5 mg/kg with amitriptyline at a dose of 5 mg/kg
did not change amitriptyline concentrations in serum and
brain (t test: p = 0.472 and p = 0.978, respectively).
Discussion
Although sildenafil displays psychotropic action both in
humans and animals (Milman and Arnold 2002; Kurt et al.
2004; Hotchkiss et al. 2005), its effect on the pathophysi-
ology of depression remains unclear. There is no direct
evidence that sildenafil may worsen or improve symptoms
of depression (Tignol et al. 2004). It has been reported that
sildenafil does not produce any effect on the behavioral
response in the forced swim test in rodents when given
alone (Almeida et al. 2006; Dhir and Kulkarni 2007a, b;
Brink et al. 2008; Savegnago et al. 2008; Brocardo et al.
2008). However, it reversed the anti-immobility action of
such substances like adenosine (Kaster et al. 2005b), me-
mantine (Almeida et al. 2006), lithium (Ghasemi et al.
2008), dizocilpine (Dhir and Kulkarni 2008), venlafaxine
(Dhir and Kulkarni 2007a), bupropion (Dhir and Kulkarni
2007b), escitalopram (Zomkowski et al. 2010), tramadol
(Jesse et al. 2008), berberine chloride (Kulkarni and Dhir
2008), diphenyl diselenide (Savegnago et al. 2008), folic
acid (Brocardo et al. 2008) and potassium channel inhibi-
tors (Kaster et al. 2005a). In our study, sildenafil did not
affect the immobility time which is in line with the above-
mentioned reports. Interestingly, it exerted anti-immobility
action after central muscarinic receptor blockade with
scopolamine. Scopolamine administered alone did not
affect animal behavior. Our results are consistent with
findings of Brink et al. (2008). In their study, sildenafil
given alone did not produce any effect on immobility time
in the forced swim test in rats nor did it reverse the anti-
immobility action of fluoxetine. Nonetheless, sildenafil
administered chronically exerted the antidepressant effect
after blocking muscarinic receptors with atropine. More-
over, in combination with atropine, sildenafil as well as
tadalafil, a potent and more selective than sildenafil PDE5
inhibitor (Rosen and McKenna 2002), exerted antidepres-
sant action in the forced swim test in FSL rats, which
represent a genetic animal model of depression (Lieben-
berg et al. 2010a). Brink et al. (2008) also showed that
sildenafil potentiates muscarinic acetylcholine receptor
signaling capacity in cultured human neuroblastoma cells
Fig. 4 Effect of desipramine administered alone and in combination
with sildenafil on immobility time in the forced swim test in mice.
Desipramine and sildenafil were administered i.p. 60 and 30 min
before the test, respectively. Control animals received saline. Each
experimental group consisted of 14–15 animals. Data are presented as
mean ? SEM. **p \ 0.01, ***p \ 0.001 as compared to control
group (one-way ANOVA followed by the Tukey’s post hoc test)
Table 1 Effect of treatments on spontaneous locomotor activity in
mice
Treatment Activity counts/
10 min
A
Saline ? saline 190.20 ± 15.18
Sildenafil (1.25 mg/kg) ? saline 168.80 ± 13.99
Sildenafil (2.5 mg/kg) ? saline 175.70 ± 13.99
Sildenafil (5 mg/kg) ? saline 183.70 ± 16.70
Sildenafil (10 mg/kg) ? saline 195.20 ± 16.03
Sildenafil (20 mg/kg) ? saline 119.60 ± 15.77
Scopolamine (0.5 mg/kg) ? saline 157.70 ± 18.68
Scopolamine (0.5 mg/kg) ? sildenafil (5 mg/kg) 180.00 ± 18.70
Amitriptyline (5 mg/kg) ? saline 140.10 ± 25.25
Amitriptyline (5 mg/kg) ? sildenafil (5 mg/kg) 157.70 ± 18.68
B
0.5% methyl cellulose ? saline 167.08 ± 21.15
Desipramine (20 mg/kg) ? saline 142.20 ± 17.23
Desipramine (20 mg/kg) ? sildenafil (20 mg/kg) 135.64 ± 11.32
Amitriptyline and sildenafil were administered i.p. 30 min before the
test whereas desipramine 60 min prior to the test. Each experimental
group consisted of 10–12 animals. Data are presented as mean ±
SEM. a One-way ANOVA: F(9, 90) = 1.789, p = 0.081; b One-way
ANOVA: F(2, 30) = 0.954, p = 0.397
Table 2 The effect of joint administration of amitriptyline and sil-
denafil on serum and brain amitriptyline concentrations in mice
Treatment Amitriptyline concentration
Serum (ng/ml) Brain (ng/g)
Amitriptyline (5 mg/kg) ? saline 93.42 ± 9.68 862.11 ± 46.28
Amitriptyline (5 mg/kg) ?
sildenafil (5 mg/kg)
102.41 ± 7.42 864.02 ± 51.45
Amitriptyline and sildenafil were administered i.p. 30 min before
decapitation. Each experimental group consisted of nine animals.
Data are presented as mean ± SEM
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and they proposed that sildenafil possesses antidepressant
properties which are attenuated or even lost because of its
simultaneous ability to enhance cholinergic transmission.
Cholinomimetic effects of sildenafil were also demon-
strated by Patil et al. (2004). Herein we report that anti-
immobility activity of sildenafil in mice can be revealed
even after its single administration with the co-adminis-
tration of scopolamine.
Sildenafil, which acts as a selective PDE5 inhibitor,
elevates intracellular cGMP level (Rosen and McKenna
2002). Phosphodiesterases, cyclic nucleotide-gated chan-
nels and cGMP-dependent protein kinase (protein kinase-
G) are the main downstream effectors of cGMP (Bryan
et al. 2009). On the ground of the observation that inhibi-
tion of protein kinase-G abolished the anti-immobility
effect of sildenafil, Liebenberg et al. (2010b) concluded
that the cholinergic-cGMP-protein kinase-G interactions
are implicated in the antidepressant action of sildenafil. It is
worth mentioning that in the absence of atropine sildenafil
at a lower dose of 3 mg/kg, but not at higher doses of 10
and 20 mg/kg, reduced immobility time and increased
climbing behavior in FSL rats. This observation suggests
the involvement of monoaminergic neurotransmission in
the animal response to sildenafil treatment (Liebenberg
et al. 2010a). PDE5 is widely distributed throughout the
brain with varying regional expression. The highest PDE5
RNA level was found in cerebellum, medulla oblongata,
substantia nigra and subthalamic nucleus (Loughney et al.
1998; van Staveren et al. 2004). For this reason, inhibition
of PDE by sildenafil may bring about various effects
including modulation of serotonergic, noradrenergic,
glutamatergic or cholinergic neurotransmitter systems.
Supposing that sildenafil enhanced the cholinergic neuro-
transmission in these brain areas which are involved in
pathophysiology of depression (e.g., hippocampus), it may
induce depressogenic effects (Liebenberg et al. 2010b).
Conversely, in the presence of an antimuscarinic agent,
antidepressant properties of sildenafil may be revealed.
In view of the above-mentioned reports, we assumed
that sildenafil may augment the activity of these antide-
pressant drugs which exhibits cholinolytic action. The
marked anticholinergic activity is a feature of many of the
tricyclic antidepressants and muscarinic receptors blockade
results in unwanted side effects including xerostomia,
constipation, tachycardia and blurred vision. There is no
clear-cut evidence that antimuscarinic effects of antide-
pressant contribute to their clinical efficacy. Thus, drugs
devoid of the effects in question were highly desirable
(Szabadi et al. 1980; Richelson 2001; Nelson 2009).
Amitriptyline is one of the most widely used tricyclic
antidepressants, which shows properties of a non-selective
muscarinic receptors antagonist (Snyder and Yamamura
1977; McKinney et al. 1988). Its affinity for these receptors
is approximately one-tenth of the affinity of atropine
(Brunton et al. 2008). The results obtained in the forced
swim test confirmed our assumption. Sildenafil at relatively
low doses caused a potent increase in the antidepressant
activity of amitriptyline. Interestingly, the highest dose of
sildenafil (5 mg/kg) caused over 90% increase of the anti-
immobility action of amitriptyline. The observed changes
in immobility time were not due to the changes in spon-
taneous locomotor activity as combined administration of
amitriptyline and sildenafil did not affect motor perfor-
mance in mice. The enhancement of antidepressant activity
of amitriptyline caused by concomitant treatment with
sildenafil may have either a pharmacodynamic or phar-
macokinetic basis. To evaluate the potential pharmacoki-
netic interaction between amitriptyline and sildenafil, brain
and serum amitriptyline concentrations were analyzed. The
results indicate that the effect observed in the forced swim
test was related to pharmacodynamic rather than pharma-
cokinetic interaction because sildenafil did not modify
amitriptyline concentrations in both examined tissues.
To establish whether the behavioral interactions
between sildenafil and amitriptyline were specifically
related to cholinolytic properties of amitriptyline, we
investigated the effect of sildenafil on the antidepressant
activity of desipramine. Among all tricyclics, desipramine
is the least potent anticholinergic agent (Nelson 2009). As
it might have been expected, sildenafil did not affect the
anti-immobility action of desipramine in the forced swim
test in mice, even though it was administered at higher
doses than in combination with amitriptyline. Because no
alteration in the antidepressant activity of desipramine after
joint administration with sildenafil was observed, there
were no rationale for assessing desipramine concentrations
in mice serum and brain tissue.
In summary, the present study demonstrates for the first
time that sildenafil enhanced the antidepressant activity of
amitriptyline in the forced swim test in mice, and this effect
was not due to a pharmacokinetic interaction. In addition,
our results constitute further support for the above-men-
tioned thesis concerning cholinomimetic action of silde-
nafil and suggest that sildenafil may augment the activity of
antidepressant drugs which exhibit antimuscarinic proper-
ties. Further studies, with the use of other animal models,
are recommended to better understanding of the observed
phenomenon.
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